| NCT06553547 | 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs | RECRUITING | PHASE2 | 2024-07-24 | 2026-06 | 2026-06 |
| NCT06203444 | An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females | COMPLETED | PHASE1 | 2023-11-27 | 2024-05-30 | 2024-05-30 |
| NCT05905926 | Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C | ENROLLING_BY_INVITATION | PHASE3 | 2023-02-17 | 2031-10 | 2031-07 |
| NCT05643534 | Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years | RECRUITING | PHASE3 | 2022-11-15 | 2025-12-31 | 2025-12-31 |
| NCT04780841 | A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia | COMPLETED | PHASE2 | 2021-01-11 | 2022-03-03 | 2021-12-28 |
| NCT04549597 | Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia | COMPLETED | PHASE4 | 2020-11-20 | 2021-12-01 | 2021-10-13 |
| NCT03988920 | A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP | COMPLETED | PHASE4 | 2019-06-15 | 2021-07-31 | 2021-06-26 |
| NCT03824587 | Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy | COMPLETED | PHASE2, PHASE3 | 2019-02-28 | 2019-07-17 | 2019-07-17 |
| NCT03427125 | A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis | COMPLETED | PHASE3 | 2018-01-08 | 2020-02-27 | 2019-11-15 |
| NCT03018067 | A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia | TERMINATED | PHASE2 | 2017-01 | 2017-05 | 2017-05 |
| NCT02727751 | A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C | COMPLETED | PHASE3 | 2016-03 | 2017-10 | 2017-10 |
| NCT02675998 | An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD) | COMPLETED | PHASE3 | 2016-01 | 2018-01-17 | 2016-12 |
| NCT02686138 | A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C | COMPLETED | PHASE3 | 2015-12 | 2017-10 | 2017-08 |
| NCT02621892 | A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C | COMPLETED | PHASE3 | 2015-10 | 2017-04 | 2017-03 |
| NCT02140268 | To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers | COMPLETED | PHASE1 | 2014-05 | 2014-08 | 2014-08 |
| NCT02140281 | To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers | COMPLETED | PHASE1 | 2014-05 | 2014-08 | 2014-08 |
| NCT02063386 | AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study | COMPLETED | PHASE1 | 2014-04 | 2014-05 | 2014-05 |
| NCT02081534 | Dose Finding Study to Treat High Phosphate Levels in the Blood. | COMPLETED | PHASE2 | 2014-03 | 2014-11 | 2014-11 |
| NCT01923428 | The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C) | COMPLETED | PHASE2, PHASE3 | 2013-08 | 2014-10 | 2014-10 |
| NCT02176252 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects | COMPLETED | PHASE1 | 2013-07 | 2013-12 | 2013-12 |
| NCT01847092 | A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria | COMPLETED | PHASE2 | 2013-05 | 2015-04 | 2015-03 |
| NCT02346890 | A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722 | COMPLETED | PHASE1 | 2013-04 | 2013-04 | 2013-04 |
| NCT02226783 | D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects | COMPLETED | PHASE1 | 2013-03 | 2013-10 | 2013-10 |
| NCT02249936 | A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations | COMPLETED | PHASE1 | 2013-02 | 2013-02 | 2013-02 |
| NCT01764854 | Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis | COMPLETED | PHASE2 | 2013-01 | 2013-10 | 2013-10 |
| NCT02796131 | Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers | COMPLETED | PHASE1 | 2011-07 | 2012-04 | 2011-10 |
| NCT01340053 | A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C) | COMPLETED | PHASE2 | 2011-05 | 2012-02 | 2011-12 |
| NCT02819687 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers | COMPLETED | PHASE1 | 2010-11 | 2011-08 | 2011-03 |